CVE-2017-12137

Description

arch/x86/mm.c in Xen allows local PV guest OS users to gain host OS privileges via vectors related to map_grant_ref.

Category

8.8
CVSS
Severity: High
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.10%
Vendor Advisory debian.org Vendor Advisory gentoo.org Vendor Advisory xen.org
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://support.citrix.com/article/CTX225941 third party advisory patch
http://www.openwall.com/lists/oss-security/2017/08/15/2 mailing list patch mitigation third party advisory
http://www.securitytracker.com/id/1039174 vdb entry third party advisory
https://bugzilla.redhat.com/show_bug.cgi?id=1477657 issue tracking third party advisory patch
http://www.debian.org/security/2017/dsa-3969 third party advisory vendor advisory
https://security.gentoo.org/glsa/201801-14 third party advisory vendor advisory
http://www.securityfocus.com/bid/100342 vdb entry third party advisory
http://xenbits.xen.org/xsa/advisory-227.html patch vendor advisory

Frequently Asked Questions

What is the severity of CVE-2017-12137?
CVE-2017-12137 has been scored as a high severity vulnerability.
How to fix CVE-2017-12137?
To fix CVE-2017-12137, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2017-12137 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2017-12137 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.